SCHEMBL25815871

SCHEMBL25815871

Bc1c([N+](=O)[O-])c(B)c2oc(CC)c(C(=O)c3cc(Br)c(O)c(Br)c3)c2c1B

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SLC22A12 Q96S37 11/20 0.49
▸ TTR P02766 8/20 0.49
▸ EYA3 Q99504 3/20 0.49
▸ CYP2C9 P11712 2/20 0.49
▸ PTPN1 P18031 2/20 0.49
▸ CYP2C19 P33261 2/20 0.49
▸ EYA2 O00167 1/20 0.49
▸ MEN1 O00255 1/20 0.49
▸ ABCC4 O15439 1/20 0.49
▸ PLIN1 O60240 1/20 0.49
▸ NR1I2 O75469 1/20 0.49
▸ USP2 O75604 1/20 0.49
▸ ABCB11 O95342 1/20 0.49
▸ ALDH1A1 P00352 1/20 0.49
▸ LMNA P02545 1/20 0.49
▸ ALB P02768 1/20 0.49
▸ ESR1 P03372 1/20 0.49
▸ NR3C1 P04150 1/20 0.49
▸ CYP1A2 P05177 1/20 0.49
▸ PGR P06401 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22680531 0.87 SLC22A12 (0.47) SLC22A12TTREYA3CYP2C9PTPN1
SCHEMBL25815944 0.85 SLC22A12 (0.56) SLC22A12TTREYA3CYP2C9PTPN1
SCHEMBL22680544 0.83 SLC22A12 (0.53) SLC22A12TTREYA3CYP2C9PTPN1
SCHEMBL24103345 0.82 SLC22A12 (0.53) SLC22A12TTREYA3CYP2C9PTPN1
SCHEMBL22680420 0.81 SLC22A12 (0.51) SLC22A12TTREYA3CYP2C9PTPN1
SCHEMBL26211216 0.78 SLC22A12 (0.53) SLC22A12TTREYA3CYP2C9PTPN1
SCHEMBL25815357 0.78 SLC22A12 (0.52) SLC22A12TTREYA3CYP2C9PTPN1
SCHEMBL26211318 0.75 SLC22A12 (0.57) SLC22A12TTREYA3CYP2C9PTPN1
SCHEMBL22680778 0.74 CYP2C19 (0.60) SLC22A12TTREYA3CYP2C9PTPN1
SCHEMBL24103648 0.74 SLC22A12 (0.50) SLC22A12TTREYA3CYP2C9PTPN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230218563-A1 METHODS FOR TREATING OR PREVENTING CHRONIC KIDNEY DISEASE ARTHROSI THERAPEUTICS, INC. 2023-07-13 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230218563-A1 METHODS FOR TREATING OR PREVENTING CHRONIC KIDNEY DISEASE ATP6V1B1, REN, CYP27B1 SLC22A12 620/4885TTR 201/4885EYA3 3141/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback